###begin article-title 0
A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia
###end article-title 0
###begin p 1
###xml 807 812 807 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 834 839 834 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 852 856 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 869 873 869 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 884 890 884 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 905 912 905 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
Numerous single nucleotide polymorphisms (SNPs) have been found in recent genome wide association studies (GWAS) to be associated with subtle plasma triglyceride (TG) variation in normolipidemic subjects. However, since these GWAS did not specifically evaluate patients with rare disorders of lipoprotein metabolism-'hyperlipoproteinemia' (HLP)-it remains largely unresolved whether any of these SNP determinants of modest physiological changes in TG are necessarily also determinants of most HLP phenotypes. To address this question, we evaluated 28 TG-associated SNPs from GWAS in 386 unrelated adult patients with one of five Fredrickson phenotypes (HLP types 2A, 2B, 3, 4 and 5) and 242 matched normolipidemic controls. We found that several SNPs associated with TG in normolipidemic samples, including APOA5 p.S19W and -1131T>C, TRIB1 rs17321515, TBL2 rs17145738, GCKR rs780094, GALNT2 rs4846914 and ANGPTL3 rs12130333, were significantly associated with HLP types 2B, 3, 4 and 5. The findings indicate that: (i) the TG-associated Fredrickson HLP types 2B, 3, 4 and 5 are polygenic traits; (ii) these Fredrickson HLP types share numerous genetic determinants among themselves; and (iii) genetic determinants of modest TG variation in normolipidemic population samples also underlie-to an apparently even greater degree-susceptibility to these rare HLP phenotypes. Thus, the TG-associated Fredrickson HLP types 2B, 3, 4 and 5, although historically considered to be distinct are actually complex traits sharing among them several common genetic determinants seen in GWAS of normolipidemic population samples.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C1">1</xref>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C4">4</xref>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C5">5</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C1">1</xref>
###xml 508 509 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C6">6</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C14">14</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C5">5</xref>
Genome-wide association studies (GWAS) have generated excitement due to the new possibilities of better understanding the genetic architecture of complex diseases (1-4), such as hyperlipidemia (5). One concern raised about GWAS in general is that the magnitude of genetic associations is relatively modest in scale, and thus possibly of limited interest or importance biologically or medically (1). For the quantitative trait of plasma lipoproteins, many familiar and new loci have emerged from recent GWAS (6-14), however, the magnitude of the genetic effects in normolipidemic samples were very modest-to an extent that many medical practitioners might question their relevance (5). One piece of evidence that would enhance the perception of the potential clinical value of these single nucleotide polymorphisms (SNPs) would be demonstration of their association with disorders that clinicians routinely diagnosis and manage.
###end p 3
###begin p 4
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C15">15</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C5">5</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C15">15</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C17">17</xref>
###xml 581 585 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C18">18</xref>
###xml 795 798 795 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 846 851 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC2</italic>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C19">19</xref>
###xml 1159 1161 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C20">20</xref>
###xml 1325 1329 1313 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1428 1429 1416 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C5">5</xref>
###xml 725 733 <span type="species:ncbi:9606">patients</span>
The Fredrickson or World Health Organization International Classification of Diseases ontology of primary hyperlipoproteinemia (HLP) types have been used as clinical and biochemical 'shorthand' by generations of physicians (15). Most Fredrickson types (), specifically HLP types 1, 2B, 3, 4 and 5 (MIM 238600, 144250, 107741, 144600 and 144650, respectively) feature elevated plasma triglyceride (TG) concentration as part of their definition (5,15-17). The exception is familial hypercholesterolemia [FH; HLP type 2A (MIM 143890)], which is often due to heterozygous mutations in LDLR encoding the low-density lipoprotein (LDL) receptor (18). In rare instances, single gene mutations have been found in hyperchylomicronemic patients with HLP type 1, particularly homozygous mutations either in LPL, which encodes lipoprotein lipase (LPL), or in APOC2, which encodes its cofactor apolipoprotein (apo) C-II (19). Thus, the genetic bases of HLP types 1 and 2A have largely been elucidated. Furthermore, approximately10% of adults with HLP type 5 have a heterozygous loss-of-function mutation in one of several genes encoding proteins involved in TG metabolism (20). However, most cases of HLP types 2B, 3, 4 and 5 are incompletely characterized at the molecular genetic level, although HLP type 3 requires homozygosity for the APOE E2 isoform as a necessary, but not sufficient, genetic condition for expression of the phenotype (5).
###end p 4
###begin p 5
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C21">21</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C22">22</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C10">10</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C15">15</xref>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
We previously found that: (1) APOA5 variants -1131T>C and p.S19W are frequently present in and strongly associated with Fredrickson types 2B, 3, 4 and 5 and also with hypertriglyceridemia (HTG) in general lipid clinic patients (21); and (2) several common SNPs, found to be contributors to subtle variation in TG concentration in normolipidemic controls, including SNPs in APOA5, APOE, TRIB1, TBL2, GCKR and GALNT2 were significant determinants of HLP type 5 (22). On the basis of these results, we hypothesized that common variants recently associated with variation in relatively normal plasma TG levels identified in GWAS (10-15) would also be associated with the remaining uncharacterized Fredrickson HLP phenotypes-namely types 2B, 3 and 4.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
Clinical, biochemical and genetic attributes in HLP cases and controls
###end title 7
###begin p 8
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB1">1</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB2">2</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Baseline demographic attributes of the 368 HLP patients and 242 normolipidemic controls are shown in Table 1. Genotype counts and frequencies among patients and controls are shown in . Minor (i.e. less common) allele frequencies for each genotype in severe HTG cases and controls are shown in Table 2. Frequencies of each genotype did not indicate deviations from Hardy-Weinberg equilibrium. Univariate odds ratios (ORs) for association between SNP genotypes-assuming dominant and recessive models-with the discrete HLP traits are shown in .
###end p 8
###begin p 9
Clinical, biochemical and genetic attributes of study subjects according to lipoprotein phenotypes
###end p 9
###begin p 10
HLP, hyperlipoproteinemia.
###end p 10
###begin p 11
Candidate gene minor allele frequencies
###end p 11
###begin p 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BUD13</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ1B</italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CILP2</italic>
###xml 523 526 523 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF4</italic>
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 599 602 599 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 638 645 638 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 682 688 682 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 723 724 723 724 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 786 791 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSRC1</italic>
###xml 942 946 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 996 1000 996 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 1034 1038 1034 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SELP</italic>
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 75 80 <span type="species:ncbi:4932">yeast</span>
###xml 165 175 <span type="species:ncbi:7227">Drosophila</span>
APOA5, gene encoding apolipoprotein A-V; BUD13, gene encoding homologue of yeast Bud13; APOC3, gene encoding apolipoprotein C-III; TRIB1, gene encoding homologue of Drosophila Tribbles 1; TBL2 locus containing genes encoding transducin-beta-like-2 and MLX interacting protein-like (also called carbohydrate response element binding protein [ChREBP]); BAZ1B, gene encoding bromodomain adjacent to zinc finger domain, 1B; GCKR, gene encoding glucokinase receptor; CILP2, gene encoding cartilage intermediate layer protein 2; SF4, gene encoding splicing factor 4; APOE, gene encoding apolipoprotein E; LPL, gene encoding lipoprotein lipase; ANGPTL3, gene encoding angiopoietin-like 3; GALNT2, gene encoding UDP-N-acetyl-alpha-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase; PSRC1, locus containing genes encoding proline/serine-rich coiled-coil 1, cadherin epidermal growth factor lag seven-pass G-type receptor 1 and sortilin 1; LDLR, gene encoding low-density lipoprotein receptor; APOB, gene encoding apolipoprotein B, SELP, gene encoding selectin P; LIPC, gene encoding hepatic lipase. Asterisk (*) indicates index marker selected for multivariate regression analyses (see text for Materials and Methods).
###end p 12
###begin title 13
Linkage disequilibrium and index SNPs for each locus
###end title 13
###begin p 14
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB2">2</xref>
Pairwise linkage disequilibrium (LD) was determined across loci (). Of the 28 variants genotyped, 17 index genotypes were selected for further statistical modeling by including only one member of a SNP genotype pair for which LD was significant and the LD correlation coefficient >0.65. Index genotypes that were selected for multivariate regression analysis are indicated in Table 2.
###end p 14
###begin title 15
Polygenic determinants of Fredrickson HLP phenotypes: multivariate regression analysis
###end title 15
###begin p 16
To assess the relationship of genotypes with HLP phenotypes, dominant and recessive models of minor allele genotypes were tested for each gene using univariate analysis (). For each significant univariate association, either the dominant or recessive variable clearly provided the stronger association; this variable was then used in subsequent analyses for the genotype.
###end p 16
###begin p 17
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB3">3</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB3">3</xref>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 563 571 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB3">3</xref>
The multivariate ORs for each HLP phenotype individually, all HLP types (2A, 2B, 3, 4 and 5) and all HTG-containing HLP types (2B, 3, 4 and 5) were calculated using the Wald statistic in multivariate logistic regression analysis with stepwise addition of variables, with P < 0.05 set for each step (Table 3A and B). Each of the five models evaluated included index genetic variables only (Table 3A), except for the model for HLP type 3, in which APOE genotype was excluded, since all those subjects had the E2/2 genotype. Age and sex were included in a series of post hoc models (Table 3B).
###end p 17
###begin p 18
Multivariate logistic regression analysis of TG-associated SNPs
###end p 18
###begin p 19
HTG, hypertriglyceridemia; NS, not significant.
###end p 19
###begin p 20
###xml 44 45 44 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB3">3</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB3">3</xref>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 529 533 529 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 649 652 649 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 698 702 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 753 760 753 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 809 813 809 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 995 1000 995 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 1022 1027 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 1040 1044 1040 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 1057 1061 1057 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 1072 1078 1072 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 1093 1100 1093 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 1275 1276 1275 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DDP361TB3">3</xref>
Significant associations are shown in Table 3A and B. Importantly, none of the genotypes are associated with HLP 2A, a trait that was defined by elevated LDL cholesterol with no elevated TG component. The C-statistic, which corresponds to the area under the receiver-operator characteristic curve for a diagnostic test, was between 0.75 and 0.80 for this combination of index genotypes (Table 3A and B). APOA5 p.S19W and -1131T>C, TRIB1 rs17321515 and TBL2 rs17145738 were significantly associated with HLP types 2B, 3, 4 and 5. GCKR rs780094 was associated with HLP types 2B and 5 only. GALNT2 rs4846914 was associated with HLP types 4 and 5 only. LPL p.S447X was only associated with HLP type 4, LIPC rs477501 was only associated with HLP type 2B and ANGPTL3 rs12130333 was only associated with HLP type 5. APOE non-E3 genotype was a defining feature of HLP type 3, but was also associated with HLP type 5 in the multivariate model. When all HTG-containing HLP types were considered together, APOA5 p.S19W and -1131T>C, TRIB1 rs17321515, TBL2 rs17145738, GCKR rs780094, GALNT2 rs4846914 and ANGPTL3 rs12130333 were significantly associated in the multivariate logistic model. Inclusion of age and sex resulted in even higher C-statistics: >0.8 in most models tested (Table 3B).
###end p 20
###begin title 21
DISCUSSION
###end title 21
###begin p 22
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 328 332 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 484 491 484 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 764 769 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C21">21</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C22">22</xref>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C21">21</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C22">22</xref>
###xml 1087 1088 1087 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C5">5</xref>
The principal novel findings in this study are: (i) several genotypes that were found by GWAS to be associated with moderate variation in plasma TG in samples without severe dyslipidemia are also associated with classical HLP phenotypes; (ii) specifically, four genotypes, namely APOA5 p.S19W and -1131C>T, TRIB1 rs17321515 and TBL2 rs17145738, were significantly associated with HLP 2B, 3, 4 and 5; (iii) other genotypes, including APOE isoforms, GCKR rs780094, GALNT2 rs4846914 and ANGPTL3 rs12130333 also had significant associations with one or two of these HLP types; and (iv) genotypes contributed to a substantial portion of susceptibility to both the discrete HLP types and to plasma TG concentrations across all HLP types. The findings of SNPs outside of APOA5 (21) associated with HLP types 2B, 3 and 4 are completely novel to the current experiments, although the current results for HLP type 5 essentially confirm our previous findings (22). Together, the previous (21,22) and current findings emphasize the complex, polygenic nature of Fredrickson HLP types 2B, 3, 4 and 5 (5), and further demonstrate that loci identified in GWAS of normolipidemic samples are also determinants of hyperlipidemia.
###end p 22
###begin p 23
###xml 726 734 <span type="species:ncbi:9606">patients</span>
The specific SNP genotypes selected for this study were based on GWAS results. In each case, the allele that was associated with the HLP phenotype in our study was also associated in the GWAS with higher plasma TG concentration. Our study indicates that these common-and so far mechanistically undefined-markers and loci are strongly and cumulatively associated with four different Fredrickson TG-associated HLP phenotypes and four of these genotypes are common across all types evaluated. This further suggests that rare loss-of-function variants in these genes, or in proximal genes for which the SNPs are markers, might also be determinants of severe HTG. Resequencing of genes marked by these SNPs should be considered in patients with HLP. But although the findings clearly link these genotypes with dyslipidemia, other factors must also be important, since genotypes studied here cumulatively accounted for only approximately20% of variation in plasma TG concentrations.
###end p 23
###begin p 24
###xml 339 341 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C20">20</xref>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 235 243 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
Our findings are consistent with the emerging model that at the extremes of a complex genetic trait, such as patients with Fredrickson HLP phenotypes are found the cumulative contributions of multiple common alleles. Furthermore, some patients, such as most of those with HLP types 1 and 2A, and approximately10% of those with HLP type 5 (20), have rare loss-of-function mutations with large effect sizes. We do not suggest that the variants studied here are directly causative for HLP phenotypes. However, the present study substantially increases the proportion of patients with Fredrickson HLP phenotypes who have a significantly associated underlying genetic predisposition. The findings reinforce that the genetic contribution to most of the Fredrickson HLP phenotypes is complex, but also suggest that additional genes or non-genetic factors may still play an important role. These might be found by performing GWAS in HLP samples themselves, as it remains possible that there might be certain determinants of these abnormal phenotypes that are not necessarily determinants of plasma lipoprotein variation within the normal range. Furthermore, the results show that significant associations can be identified by studying a relatively small number of subjects with extreme values of a quantitative lipoprotein trait. Finally, re-sequencing genes at GWAS loci may reveal new rare loss-of-function mutations.
###end p 24
###begin title 25
MATERIALS AND METHODS
###end title 25
###begin title 26
Subjects
###end title 26
###begin p 27
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C23">23</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C23">23</xref>
###xml 106 114 <span type="species:ncbi:9606">Patients</span>
###xml 662 670 <span type="species:ncbi:9606">patients</span>
###xml 875 883 <span type="species:ncbi:9606">patients</span>
We studied 386 consecutive unrelated subjects of European ancestry from a tertiary referral lipid clinic. Patients underwent a complete medical history and examination; basic clinical, biochemical and demographic variables were collected. Normolipidemic adult controls were taken from the European subgroup of the Study of Health Assessment and Risk in Ethnic groups, a survey of cardiovascular risk factors in Canadian sub-populations (23) together with healthy population-based controls from Ontario. Using a validated sampling strategy (23), households of Caucasian ethnicity within essentially the same geographic locale as the catchment area from which the patients were referred were randomly selected and mailed an introductory letter, followed by up to 12 telephone calls inviting the individual with the earliest date of birth from the household to participate. All patients provided informed consent for DNA analysis (University of Western Ontario Institutional Review Board protocol #07920E).
###end p 27
###begin title 28
Biochemical determinations and classification by HLP phenotype
###end title 28
###begin p 29
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C21">21</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C23">23</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C24">24</xref>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1000 1002 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C21">21</xref>
###xml 1567 1570 1563 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 1574 1579 1570 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC2</italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 1439 1447 <span type="species:ncbi:9606">children</span>
Plasma lipoprotein profiles were determined as described for adult (age >18 years) lipid clinic patients (21) and for normal controls (23). Subjects were classified as having familial hypercholesterolemia (FH; HLP type 2A) based on the presence of definite diagnostic criteria (24), which in all cases included demonstration of heterozygosity for a disease-causing mutation. Subjects were classified as having HLP type 2B (combined hyperlipidemia) on the basis of both cholesterol and TG higher than age- and sex-specific 95th and 90th percentile values, respectively, together with the presence of cholesterol or TG higher than age- and sex-specific 90th percentile values in a blood relative. Subjects were classified as having HLP type 3 (dysbetalipoproteinemia) based on the presence of an APOE E2/E2 homozygous genotype, TG exceeding age- and sex-specific 90th percentile values and/or documentation of a ratio of very-low density lipoprotein cholesterol to TG >/=0.30, determined as described (21). Subjects were classified as having HLP type 4 (primary HTG) based on TG concentrations exceeding age- and sex-specific 90th percentile values, but not exceeding 10 mmol/l, with no documented chylomicronemia and absence of other lipoprotein phenotypes. Subjects were classified has having HLP type 5 (mixed hyperlipidemia) based on fasting plasma TG >10 mmol/l documented on >/=2 occasions with documented chylomicronemia. We excluded children with fasting plasma TG >10 mmol/l with documented chylomicronemia and homozygous or compound heterozygous mutations in LPL or APOC2.
###end p 29
###begin title 30
DNA analysis
###end title 30
###begin p 31
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C25">25</xref>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C6">6</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C14">14</xref>
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC3</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C26">26</xref>
###xml 258 261 258 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C20">20</xref>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 349 354 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BUD13</italic>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TBL2</italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAZ1B</italic>
###xml 449 453 449 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CILP2</italic>
###xml 496 499 496 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF4</italic>
###xml 512 515 512 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 554 561 554 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 588 594 588 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 609 613 609 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSRC1</italic>
###xml 776 780 776 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 792 796 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 807 811 807 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SELP</italic>
###xml 890 894 890 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 987 991 987 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
DNA was extracted as described (25). Markers were selected based on their association (or the association of their genetic locus) with plasma TG in at least two reports (6-14). APOA5 p.S19W and -1131C>T (dbSNP rs662799), APOC3 482C>T, APOE isotypes (26) and LPL p.S447X (20) were genotyped as described. Genotypes of APOA5 rs6589566 and rs12286037, BUD13 rs964184 and rs28927680, TRIB1 rs17321515 and rs2954029, TBL2 rs17145738 and BAZ1B rs2074755, GCKR rs780094 and rs1260326, CILP2 rs16996148, SF4 rs10401969, LPL rs10503669, rs17482753 and rs6993414, ANGPTL3 rs12130333 and rs1748195, GALNT2 rs4846914 and LIPC rs4775041 were determined using TaqMan based protocols and reagents (Applied Biosystems). We also genotyped LDL cholesterol (not TG)-related SNPs PSRC1 rs599839, LDLR rs6511720, APOB rs693 and SELP rs3917820 using TaqMan based protocols and reagents (Applied Biosystems). For APOE, presence or absence of the common E3/3 genotype was evaluated, except in HLP type 3, since APOE E2/2 isotype was considered to be part of the phenotypic definition. A random 5% of genotypes were repeated on a different day; the concordance rate exceeded 99.9% for all markers studied.
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP361C27">27</xref>
###xml 1015 1016 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The two-sample t-test was used to compare the difference between case and control groups for quantitative traits, although Pearson's chi-square test was used to compare discrete traits with exact P-values obtained whenever cell sizes <5. Deviations of genotype frequency from the Hardy-Weinberg assumption were assessed using a chi-square test. Maximal likelihood LD was estimated as described (27). To assess the relationship of genotypes with HLP phenotypes, dominant and recessive models of minor allele genotypes were tested for each gene. Since we were most interested in the polygenic nature of these traits, we used a multiple logistic regression model with backward elimination to assess the joint effects of SNP genotypes on HLP phenotypes. For a genotype with frequency 0.20, the study sample afforded statistical power (alpha error level = 0.05) to detect 1.4-, 1.6-, 1.8- and 2.0-fold increases in frequency of 59.1, 85.7, 96.9 and 99.9%, respectively. Statistical significance was taken at a two-sided P-value <0.05 for all comparisons. Most analyses were performed using SAS version 9.1 (SAS Institute), whereas exact tests were performed using StatXact8 (Cytel Inc.).
###end p 33
###begin title 34
FUNDING
###end title 34
###begin p 35
###xml 28 79 28 79 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Jacob J. Wolfe Distinguished Medical Research Chair</funding-source>
###xml 85 154 85 154 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics</funding-source>
###xml 160 207 160 207 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Jean Davignon Award for Cardiovascular Research</funding-source>
###xml 226 299 226 299 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Career Investigator award from the Heart and Stroke Foundation of Ontario</funding-source>
###xml 301 340 301 340 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Canadian Institutes for Health Research</funding-source>
###xml 342 373 342 373 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MOP-13430, MOP-39533, MOP-39833</award-id>
###xml 376 414 376 414 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Heart and Stroke Foundation of Ontario</funding-source>
###xml 416 441 416 441 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRG-5967, NA-6059, T-6018</award-id>
###xml 444 522 444 522 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ontario Research Fund and Genome Canada through the Ontario Genomics Institute</funding-source>
###xml 140 145 <span type="species:ncbi:9606">Human</span>
This work was supported by: Jacob J. Wolfe Distinguished Medical Research Chair; the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics; the Jean Davignon Award for Cardiovascular Research (Pfizer, Canada); Career Investigator award from the Heart and Stroke Foundation of Ontario; Canadian Institutes for Health Research (MOP-13430, MOP-39533, MOP-39833); Heart and Stroke Foundation of Ontario (PRG-5967, NA-6059, T-6018); Ontario Research Fund and Genome Canada through the Ontario Genomics Institute. Funding to pay the Open Access charge was provided by Genome Canada through the Ontario Genomics Institute.
###end p 35
###begin title 36
Supplementary Material
###end title 36
###begin title 37
[Supplementary Data]
###end title 37
###begin title 38
ACKNOWLEDGEMENTS
###end title 38
###begin p 39
Salam Al-Attar, Tim Lin, Rebecca Pollex, Ryan Huff, Arya Zandvakili, Sana Ibrahim, Rana Chakrabarti, Thorsten Kragh, Adam Romanowski, Edmond Luk, Rachel Danielson and Reina Hassell provided technical assistance.
###end p 39
###begin p 40
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 40
###begin title 41
REFERENCES
###end title 41
###begin article-title 42
###xml 29 34 <span type="species:ncbi:9606">human</span>
Common genetic variation and human traits
###end article-title 42
###begin article-title 43
###xml 35 40 <span type="species:ncbi:9606">human</span>
Genomewide association studies and human disease
###end article-title 43
###begin article-title 44
Genomewide association studies: illuminating biologic pathways
###end article-title 44
###begin article-title 45
Genetic risk prediction: are we there yet?
###end article-title 45
###begin article-title 46
Plasma lipoproteins: genetic influences and clinical implications
###end article-title 46
###begin article-title 47
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts
###end article-title 47
###begin article-title 48
Polymorphisms associated with cholesterol and risk of cardiovascular events
###end article-title 48
###begin article-title 49
###xml 129 135 <span type="species:ncbi:9606">humans</span>
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans
###end article-title 49
###begin article-title 50
Common variants at 30 loci contribute to polygenic dyslipidemia
###end article-title 50
###begin article-title 51
Genome-wide association analysis of metabolic traits in a birth cohort from a founder population
###end article-title 51
###begin article-title 52
LDL-cholesterol concentrations: a genome-wide association study
###end article-title 52
###begin article-title 53
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
###end article-title 53
###begin article-title 54
Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia
###end article-title 54
###begin article-title 55
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
###end article-title 55
###begin article-title 56
A system for phenotyping hyperlipoproteinemia
###end article-title 56
###begin article-title 57
Genetic basis of lipoprotein disorders
###end article-title 57
###begin article-title 58
Genetics of atherosclerosis
###end article-title 58
###begin article-title 59
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
###end article-title 59
###begin article-title 60
Hypertriglyceridemia: phenomics and genomics
###end article-title 60
###begin article-title 61
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650)
###end article-title 61
###begin article-title 62
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia
###end article-title 62
###begin article-title 63
Polygenic determinants of severe hypertriglyceridemia
###end article-title 63
###begin article-title 64
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)
###end article-title 64
###begin article-title 65
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease
###end article-title 65
###begin article-title 66
Are Canadian Inuit at increased genetic risk for coronary heart disease?
###end article-title 66
###begin article-title 67
Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites
###end article-title 67
###begin article-title 68
Linkage disequilibrium between DNA markers at the low-density lipoprotein receptor gene
###end article-title 68

